drugset / Trial / NCT06161493
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This Phase I, open label, dose determining study of oral niraparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with metastatic or recurrent solid cancer. Dose escalation will follow the mTPI-2/Keyboard design. Eligible patients will receive therapy until disease progression or unacceptable toxicities are experienced.
Timeline
- Start
- 2024-01-23
- Primary completion
- 2026-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | 100 mg | Oral |
| Subject | Niraparib | Small molecule | 200 mg | Oral |
| Subject | ZEN-3694 | Small molecule | 36 mg | Oral |
| Subject | ZEN-3694 | Small molecule | 48 mg | Oral |